Deltex Medical Group launches 'TrueVue' haemodynamic monitoring system

Oesophageal doppler monitoring company Deltex Medical Group announced the launch of a “revolutionary concept” in advanced haemodynamic monitoring on Tuesday - the ‘TrueVue’ system.

The AIM-traded firm said the TrueVue system comprised three “distinct best-in-class” advanced haemodynamic monitoring technologies on a single platform.

They included the TrueVue Doppler - a “high-end” ODM technology providing beat-to-beat imaging of cardiac output for monitoring sedated patients and easy calibration and recalibration of arterial pressure cardiac output.

It also included TrueVue Impedance - a non-invasive, high definition impedance cardiography for monitoring awake patients, both mobile and immobile.

The final monitoring technology was TrueVue Loops,, described as unique real-time biomarkers for early detection of hypo- and hyper-volaemia, hypo- and hyper-tension and real-time display of responses to treatment.

Deltex said the TrueVue system was being featured at its booth at Anesthesiology 2017, the annual meeting of the American Society of Anesthesiologists in Boston, Massachusetts.

It added that use of TrueVue Impedance in the US remained subject to FDA approval, with the submission made but not yet granted.

“The launch of the TrueVue system on the CardioQ-ODM+ platform is an exciting development for the company,” said Deltex chief executive Ewan Phillips.

“It means we will now be marketing the world's first haemodynamic monitoring system which can be used across the whole patient pathway from awake, mobile outpatients of all ages through to sedated, critical care patients.”

Phillips said the TrueVue system could be used by trainee staff, in non-critical situations, through to experienced specialists.

“It will also broaden the company's addressable market and positions us to supply hospitals with all their haemodynamic monitoring requirements on a single platform.”